These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19538112)

  • 41. Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine.
    Cohn AC; MacNeil JR; Harrison LH; Lynfield R; Reingold A; Schaffner W; Zell ER; Plikaytis B; Wang X; Messonnier NE;
    Pediatrics; 2017 Feb; 139(2):. PubMed ID: 28100689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature.
    Balmer P; Burman C; Serra L; York LJ
    Hum Vaccin Immunother; 2018 May; 14(5):1118-1130. PubMed ID: 29565712
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
    J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Carriage rate and effects of vaccination after outbreaks of serogroup C meningococcal disease, Brazil, 2010.
    Sáfadi MA; Carvalhanas TR; Paula de Lemos A; Gorla MC; Salgado M; Fukasawa LO; Gonçalves MG; Higa F; Brandileone MC; Sacchi CT; Ribeiro AF; Sato HK; Bricks LF; Cassio de Moraes J
    Emerg Infect Dis; 2014 May; 20(5):806-11. PubMed ID: 24751156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps.
    LaForce FM; Djingarey M; Viviani S; Preziosi MP
    Hum Vaccin Immunother; 2018 May; 14(5):1098-1102. PubMed ID: 28968148
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can we control all-cause meningococcal disease in Europe?
    Sadarangani M; Pollard AJ
    Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S103-S112. PubMed ID: 27129415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease.
    Anderson AS; Hao L; Jiang Q; Harris SL; Jones TR; Perez JL; York L; Eiden J; Jansen KU
    Hum Vaccin Immunother; 2013 Mar; 9(3):471-9. PubMed ID: 23249817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?
    Findlow H; Borrow R
    Hum Vaccin Immunother; 2015; 11(6):1501-6. PubMed ID: 25912095
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meningococcal vaccines: current issues and future strategies.
    Cohn AC; Harrison LH
    Drugs; 2013 Jul; 73(11):1147-55. PubMed ID: 23839656
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Meningococcal conjugate vaccines: efficacy and new combinations.
    Sáfadi MA; Barros AP
    J Pediatr (Rio J); 2006 Jul; 82(3 Suppl):S35-44. PubMed ID: 16826310
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of meningococcal serogroup C vaccine programmes.
    Borrow R; Abad R; Trotter C; van der Klis FR; Vazquez JA
    Vaccine; 2013 Sep; 31(41):4477-86. PubMed ID: 23933336
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study.
    Ohm M; Hahné SJM; van der Ende A; Sanders EAM; Berbers GAM; Ruijs WLM; van Sorge NM; de Melker HE; Knol MJ
    Clin Infect Dis; 2022 Jul; 74(12):2173-2180. PubMed ID: 34525199
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent Progress in the Prevention of Serogroup B Meningococcal Disease.
    Feavers IM; Maiden MCJ
    Clin Vaccine Immunol; 2017 May; 24(5):. PubMed ID: 28356256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meningococcal Carriage Following a Vaccination Campaign With MenB-4C and MenB-FHbp in Response to a University Serogroup B Meningococcal Disease Outbreak-Oregon, 2015-2016.
    McNamara LA; Thomas JD; MacNeil J; Chang HY; Day M; Fisher E; Martin S; Poissant T; Schmink SE; Steward-Clark E; Jenkins LT; Wang X; Acosta A;
    J Infect Dis; 2017 Nov; 216(9):1130-1140. PubMed ID: 28968661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection.
    Borrow R; Alarcón P; Carlos J; Caugant DA; Christensen H; Debbag R; De Wals P; Echániz-Aviles G; Findlow J; Head C; Holt D; Kamiya H; Saha SK; Sidorenko S; Taha MK; Trotter C; Vázquez Moreno JA; von Gottberg A; Sáfadi MA;
    Expert Rev Vaccines; 2017 Apr; 16(4):313-328. PubMed ID: 27820969
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.
    Trotter CL; Edmunds WJ
    Med Decis Making; 2006; 26(1):38-47. PubMed ID: 16495199
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe.
    Bai X; Borrow R; Bukovski S; Caugant DA; Culic D; Delic S; Dinleyici EC; Eloshvili M; Erdősi T; Galajeva J; Křížová P; Lucidarme J; Mironov K; Nurmatov Z; Pana M; Rahimov E; Savrasova L; Skoczyńska A; Smith V; Taha MK; Titov L; Vázquez J; Yeraliyeva L
    J Infect; 2019 Dec; 79(6):528-541. PubMed ID: 31682877
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.
    Borrow R; Andrews N; Goldblatt D; Miller E
    Infect Immun; 2001 Mar; 69(3):1568-73. PubMed ID: 11179328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.